Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
Recruiting
N/A
Interventional Study
Metastatic Melanoma
Skin Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 100 (estimated)
- Sponsor
- Institute of Oncology Ljubljana · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the efficacy of immunotherapy in the first-line treatment of metastatic melanoma in Slovenia and to investigate the association between PD-L1 expression and treatment response. The study aims to determine the relationship between exosomal PD-L1 miRNA expression, PD-L1 expression in tumor tissue, and PD-L1 expression on the surface of immune cells, and respo…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years
* Cytologically or histologically confirmed metastatic malignant melanoma
* Stage IIID unresectable or stage IV (AJCC 8th edition)
* ECOG performance status 0-2
* First-line systemic immunotherapy (pembrolizumab, nivolumab, or ipilimumab/nivolumab)
* CT/PET-CT pe…
Contacts